Zimmer Biomet Holdings (ZBH) opened Q1 2026 with revenue of US$2.1b and basic EPS of US$1.22, while trailing twelve month EPS stood at US$3.86 on revenue of US$8.4b. Over recent quarters, revenue has moved from US$1.9b in Q1 2025 to US$2.1b in Q1 2026. Basic EPS shifted from US$0.92 to US$1.22 across the same periods, setting up a quarter where compressed net margins are front and center for investors parsing the quality of the result.

See our full analysis for Zimmer Biomet Holdings.

With the headline numbers on the table, the next step is to line them up against the key Zimmer Biomet narratives to see which stories hold up and which need a rethink.

Margins Under Pressure At 9.1%

• Trailing net profit margin sits at 9.1%, compared to 11.9% a year earlier, while trailing twelve month net income is US$761.2 million on US$8.4b of revenue. This frames the current profitability backdrop for Q1 2026.
• Consensus narrative highlights margin expansion potential from robotics, digital health and a higher mix of premium implants. However, the recent move from 11.9% to 9.1% shows that margin pressure is still present today, especially with a one off loss of US$271.0 million in the last 12 months and integration costs from acquisitions weighing on current results.
  • Supporters of the bullish case point to ROSA and other data driven platforms as long term drivers of better margins, but the latest trailing margin level indicates those benefits are not fully reflected in reported numbers yet.
  • At the same time, bears who worry about pricing pressure and reimbursement headwinds will see the year over year margin compression as consistent with their concerns, even as management talks about efficiencies and portfolio optimization.

On this set of numbers, bulls and bears are looking at the same 9.1% margin and drawing very different conclusions about what comes next, so it can help to see how each side builds its case in more detail 🐂 Zimmer Biomet Holdings Bull Case

EPS Trend Mixed Against Five Year History

• Basic EPS for Q1 2026 is US$1.22, with trailing twelve month EPS at US$3.86, compared with a five year history that averaged 11.6% annual EPS growth but recorded negative earnings growth in the most recent year.
• Bears argue that rising competition, regulatory timing on robotics and execution risk around acquisitions could keep earnings growth choppy. The combination of slower trailing revenue growth of 3.3% per year and the recent one off US$271.0 million loss provides support for that cautious view.
  • EPS across the last four reported quarters has swung between US$0.71 and US$1.22, which lines up with concerns about earnings volatility during integration of Paragon 28 and Monogram Technologies.
  • With net profit margin stepping down over the year at the same time that leverage is described as high, skeptics can point to less room for error if new products or acquisitions do not ramp as smoothly as hoped.

🐻 Zimmer Biomet Holdings Bear Case

Valuation Signals Versus Slower 3.3% Growth

• At a current share price of US$82.80, the stock trades on a P/E of 21.1x compared with peer and industry averages of 36.2x and 25x. The DCF fair value cited here is US$172.58 and the single allowed analyst price target reference is US$101.81, all alongside trailing revenue growth of 3.3% per year.
• Consensus narrative leans on procedure growth from an aging population, robotics adoption and portfolio optimization to support revenue and earnings over time. Yet the recent 3.3% trailing revenue growth rate and year over year margin step down show that the shift from this slower recent backdrop to those future assumptions is still a work in progress.
  • Supportive factors include the current P/E discount to peers and the gap between the US$82.80 share price and the DCF fair value of US$172.58, which many investors will notice when comparing alternatives.
  • Balancing that, the combination of high debt, the US$271.0 million one off loss and slower trailing top line growth gives a factual basis for more cautious readers to question how quickly the business can move from this baseline to the stronger analyst scenarios that underpin the US$101.81 target.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Zimmer Biomet Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals in the numbers and narratives can be confusing, so act while the earnings story is fresh and weigh both the 4 key rewards and 2 important warning signs

See What Else Is Out There

Zimmer Biomet's compressed 9.1% margin, one off US$271.0 million loss and high debt level all point to meaningful financial pressure and less resilience.

If those balance sheet and earnings pressures make you cautious, it is a good time to compare with companies in the solid balance sheet and fundamentals stocks screener (44 results) that aim to pair sturdier finances with more predictable performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.